United States Melanoma Therapeutics Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Global Melanoma Therapeutics Market reached US$ 5.40 billion in 2024 and is expected to reach US$ 8.35 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2025-2032.

Recent Mergers and acquisitions:

United States:

✅ In July 2025, IO Biotech initiated a pivotal Phase 3 trial (IOB-013/KN-D18) for its cancer vaccine Cylembio® in combination with KEYTRUDA® for advanced melanoma. The trial is progressing as planned, with results expected in Q3 2025.

✅ In March 2025, Replimune's RP1 melanoma therapy neared an FDA decision, with a PDUFA date set for July 2025. The company is preparing its commercial infrastructure for a potential launch.

✅ In August 2024, Roche announced plans to acquire Poseida Therapeutics for approximately $1.5 billion. Poseida's expertise in allogeneic CAR-T cell therapies is anticipated to complement Roche's oncology portfolio, including melanoma treatments

✅ In February 2024, Iovance Biotherapeutics received FDA accelerated approval for Lifileucel (Amtagvi), the first T-cell therapy for advanced melanoma after PD-1 and BRAF inhibitors. This approval marks a significant milestone in personalized cancer treatment.

Japan:

✅ In April 2025, the National Cancer Center Japan announced a new president, signaling a renewed focus on advancing cancer research and treatment strategies, including for melanoma.

✅ In January 2025, Japan launched the "ARCAD-Gastric" global clinical trial database project, aiming to enhance research capabilities, which may include studies on melanoma therapies.

✅ In September 2024, Astellas Pharma finalized its acquisition of a Japanese biotech company specializing in melanoma vaccines. This strategic acquisition aims to diversify Astellas's oncology portfolio and accelerate the development of melanoma immunotherapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/melanoma-therapeutics-market?sb

Melanoma Therapeutics are treatments designed to manage and cure melanoma, a serious form of skin cancer. These include targeted therapies, immunotherapies, chemotherapy, and surgical interventions, aimed at inhibiting tumor growth, preventing metastasis, and improving patient survival and quality of life.

Key Players:

=> Merck & Co., Inc., Bristol-Myers Squibb Company., Amgen, Inc., IOVANCE Biotherapeutics, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Immunocore Holdings plc., Eisai Co., Ltd., and Delcath Systems, Inc. among others.

Growth Forecast Projected:

The Global Melanoma Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Melanoma Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=melanoma-therapeutics-market

Key Segments:

➥ By Type: Superficial Spreading Melanoma, Nodular Melanoma, Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Others
➥ By Therapy: Surgery, Immunotherapy (Pembrolizumab, Nivolumab, Ipilimumab, Lifileucel, Others), Targeted Therapy (BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors), Chemotherapy, Radiation Therapy

Regional Analysis for Melanoma Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Melanoma Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Melanoma Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/melanoma-therapeutics-market?sb

FAQ

What is the current size of the Melanoma Therapeutics Market?

A: In 2024, the Melanoma Therapeutics Market was valued at US$ 5.40 billion, reflecting its strong industry presence.

Q2: How large is the Melanoma Therapeutics Market expected to be by 2032?

A: By 2032, industry forecasts suggest the Melanoma Therapeutics Market will grow to around US$ 8.35 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Melanoma Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.6% during the forecast period from 2025 to 2032.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.